You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Exact Sciences discussed new Cologuard data; Danaher reviewed Cepheid's 2020 performance; and NanoString talked about forthcoming spatial biology products.
The Seattle-based firm expects product and service revenues of $35.7 million in the fourth quarter and $111.4 million in Fiscal Year 2020.
The index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in December.
New cellular and molecular spatial biology methods, companies, and product offerings have made this area one of the hottest in the life science market.
The spatial molecular imager will be NanoString's next play in a growing market that it says is worth more than $12 billion, including diagnostic applications.
A new GeoMx Digital Spatial Profiler assay will have up to 30 protein targets and will be validated for potential use as a laboratory-developed test.
In PLOS this week: method that combines genetic and lab test results from EHRs, leptospirosis microtranscriptome profiles, and more.
The Seattle-based genomics technology firm saw revenues grow 20 percent on a pro forma basis, driven by 60 percent growth in instrument revenue.
The GenomeWeb Index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, which all fell in October.
Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.
In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.